Jam

Nano One Materials Corp. (NNOMF) reported Q2 2025 results with $23.2M net assets and $22.8M working capital. They secured $3.6M in government funding but reported a $2.8M net loss. Key developments include selection for the Arkansas Lithium Technology Accelerator (ALTA) program, recognition by the IEA as a top LFP innovator, and commencing trading on the U.S. OTCQB market. Approximately $25.0M in government program reimbursements remain to be claimed over the next two years.

Interactive Brokers has launched IBKR Lite in Singapore, offering commission-free trading of US stocks and ETFs around the clock. This plan eliminates commissions, platform, and settlement fees, providing Singaporean investors with cost-effective access to US markets. IBKR Lite complements the IBKR Pro plan, allowing clients to choose between the two. Singaporean investors also gain access to global markets, trading in multiple currencies, fractional shares, and AI-powered news. This launch intensifies competition in Singapore’s online brokerage space.

Axcap Ventures (GARLF) extended its milestone payment deadline with Waterton Nevada Splitter LLC from July 15, 2025, to September 30, 2025. In exchange, Axcap issued 1,550,000 common shares to Waterton, subject to a four-month-and-one-day lock-up period. The extension modifies the original milestone payment rights agreement dated July 15, 2024. Axcap focuses on undervalued resources in the USA and Canada aiming to build a portfolio of development-ready gold resources.

Simon Property Group’s operating partnership is selling $1.5 billion in senior notes due 2030 and 2035 with a weighted average coupon of 4.775%. The offering, managed by firms like BBVA and J.P. Morgan, is expected to close on August 19, 2025. Proceeds will be used to redeem $1.1 billion in notes maturing in September 2025 and for general corporate purposes, potentially reducing unsecured debt. This move aims to optimize Simon’s debt profile amid changing interest rates. Risks include market conditions and forward-looking statements.

PetMed Express (PETS) announced the resignation of CEO Sandra Campos and CFO Robyn D’Elia. Board Chair Leslie C.G. Campbell is now Interim CEO, and Douglas Krulik is Interim Principal Financial Officer. The departing executives will receive severance packages, including 13 months’ salary and vested stock units, and will provide consulting for three months. The company is seeking permanent CEO and CFO replacements. Justin Mennen is Lead Independent Director, and the Audit and Compensation committees have new chairs.

VIP Play, Inc. and Vokol are partnering to introduce AI-driven, personalized audio experiences for sports fans. The collaboration will be showcased at the AI4 Conference in Las Vegas on August 13th, with a live demonstration by VIP Play CEO Les Ottolenghi. Vokol’s AI audio platform aims to revolutionize sports content creation, enabling rapid production of high-quality audio. This partnership aims to redefine fan engagement by blending AI technology with authentic storytelling.

Photronics (PLAB) will participate in three investor conferences: Oppenheimer’s Technology Conference (virtual, Aug 13), TD Cowen’s Technology Growth Cap Summit (NYC, Sept 4), and Singular Research Investor Conference (NYC, Sept 10). Institutional investors should contact their representatives at the respective firms to participate. Photronics, a photomask technology leader, aims to provide insights into its strategy and the microelectronics landscape. The company has 11 manufacturing facilities across Asia, Europe and North America.

Hemostemix (HMTXF) has contracted Empire Market Ventures (EMV) to boost its market awareness. EMV, a New York-based consulting firm specializing in investor relations and strategic communications, will develop and implement investor engagement strategies using digital media and market intelligence. EMV will operate independently to provide unbiased counsel and ensure regulatory compliance. The goal of the partnership is to increase Hemostemix’s visibility and growth within the capital markets. The announcement was made on August 12, 2025.

ETHZilla (formerly 180 Life Sciences) announced it has accumulated 82,186 ETH, valued at approximately $349 million, with an average purchase price of $3,806.71. The company also maintains $238 million in USD cash equivalents. ETHZilla plans to generate yield from its ETH holdings through staking strategies managed by Electric Capital. The company is pivoting towards software-enabled gaming and entertainment, aiming to be a leader in on-chain treasury management and will provide regular updates on its progress.

Merck’s KEYNOTE-905 (EV-303) trial showed positive results for muscle-invasive bladder cancer (MIBC) patients ineligible for cisplatin-based chemotherapy. The study combined KEYTRUDA (pembrolizumab) and Padcev (enfortumab vedotin-ejfv) before and after surgery, demonstrating statistically significant and clinically meaningful improvement in event-free survival (EFS), overall survival (OS), and pathologic complete response (pCR) compared to surgery alone. This represents the first systemic therapy to improve survival in this population, potentially establishing a new standard of care. The treatment’s safety profile was consistent with existing data.